Sunday, May 29, 2022 4:57:22 PM
My feeling is no way we're still going to have the article published by ASCO (which starts Fri. 6/3).
The move to let LL present at NYAS probably opened a side door for dcvax and the trial to be discussed at ASCO not by NWBO (at least not in any public venue), but for non-employee docs like Ashkan to talk - maybe those guys even not in more public venues but who knows how much they can do given LL's slides. No doubt that was the main purpose behind letting the cat out of the bag even without having the article ready for immediate rebuttal, in my humble guess.
That was a huge gamble/trade off; assuming no article out because the company cannot talk, yet ASCO is an opportunity not to be missed as I understand the significance of that industry 'everybody is there' type meeting. Anyway that is my best thinking on why they took the huge risk to the stock of presenting and giving AF and the cabal an open target when the company cannot even publically respond to him. The dynamic with him and the cabal made it hugely predictable that the stock would be hit.
As for the stock action, actually the stock moved from .70 to 1.00 and then super fast to 2.00; imo that is important to keep in mind because NWBO must have put plans in place for the NYSA reveal well before the almost 3x gain from .70 - remember that that gain is a part of the huge disappointment to longs like me who were primed by our knowledge to expect a further run up from 2.00 on the initial TLD mini-disclosure.
In hindsight it did seem like a super dumb thing to do, given the resulting effect on the stock; but not so much if they had put the plans in to get non-peer-reviewed results in the open for possibility for non-NWBO principal investors to speak out at ASCO and for the company itself to meet with lots of various professionals at ASCO in private discussions maybe completely limited to an 'as disclosed by LL' basis, maybe not - who knows what they say in private conversations.
I was as dismayed as anyone, please be sure of that, with the LL-AF-stock fiasco. But LP and LG are NOT idiots. There had to be a method to their madness in setting us all for the perfect storm to crash the stock (very temporarily I hope!!!).
The move to let LL present at NYAS probably opened a side door for dcvax and the trial to be discussed at ASCO not by NWBO (at least not in any public venue), but for non-employee docs like Ashkan to talk - maybe those guys even not in more public venues but who knows how much they can do given LL's slides. No doubt that was the main purpose behind letting the cat out of the bag even without having the article ready for immediate rebuttal, in my humble guess.
That was a huge gamble/trade off; assuming no article out because the company cannot talk, yet ASCO is an opportunity not to be missed as I understand the significance of that industry 'everybody is there' type meeting. Anyway that is my best thinking on why they took the huge risk to the stock of presenting and giving AF and the cabal an open target when the company cannot even publically respond to him. The dynamic with him and the cabal made it hugely predictable that the stock would be hit.
As for the stock action, actually the stock moved from .70 to 1.00 and then super fast to 2.00; imo that is important to keep in mind because NWBO must have put plans in place for the NYSA reveal well before the almost 3x gain from .70 - remember that that gain is a part of the huge disappointment to longs like me who were primed by our knowledge to expect a further run up from 2.00 on the initial TLD mini-disclosure.
In hindsight it did seem like a super dumb thing to do, given the resulting effect on the stock; but not so much if they had put the plans in to get non-peer-reviewed results in the open for possibility for non-NWBO principal investors to speak out at ASCO and for the company itself to meet with lots of various professionals at ASCO in private discussions maybe completely limited to an 'as disclosed by LL' basis, maybe not - who knows what they say in private conversations.
I was as dismayed as anyone, please be sure of that, with the LL-AF-stock fiasco. But LP and LG are NOT idiots. There had to be a method to their madness in setting us all for the perfect storm to crash the stock (very temporarily I hope!!!).
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
